Has the practice of radiation oncology for locally advanced and metastatic non-small-cell lung cancer changed in Canada?
OBJECTIVE
Previous surveys have revealed wide variations in the management by radiation oncologists of non-small-cell lung cancer (NSCLC) in Canada. The aim of the present study was to determine the current patterns of practice for locally advanced and metastatic NSCLC among Canadian radiation oncologists.


METHODS
An online survey was distributed electronically to all members of the Canadian Association of Radiation Oncologists. Those who treat lung cancer were invited to participate. The survey consisted of three scenarios focusing on areas of nsclc treatment in which the radiotherapy (RT) regimen that provides the best therapeutic ratio is unclear.


RESULTS
Replies from 41 respondents were analyzed. For an asymptomatic patient with stage IIIB NSCLC unsuitable for radical treatment, 22% recommended immediate RT, and 78% recommended RT only if the patient were to become symptomatic. Those who believed that immediate RT prolongs survival were more likely to recommend it (p = 0.028). For a patient with a bulky stage IIIB tumour and good performance status, 39% recommended palliative treatment, and 61% recommended radical treatment (84% concurrent vs. 16% sequential chemoradiation at 60-66 Gy in 30-33 fractions). Those who believed that chemoradiation has a greater impact on survival were more likely to recommend it (p < 0.001). For a symptomatic patient with stage IV NSCLC, 54% recommended external-beam RT (EBRT) alone, 41% recommended other modalities (brachytherapy, endobronchial therapy, or chemotherapy) with or without EBRT, and 5% recommended best supportive care. A majority (76%) prescribed 20 Gy in 5 fractions for EBRT.


CONCLUSIONS
Compared with previous surveys, more radiation oncologists now offer radical treatment for locally advanced NSCLC. Management of nsclc in Canada may be evidence-based, but perception by radiation oncologists of the treatment's impact on survival also influences treatment decisions.
Han
K
K
Department of Radiation Oncology, Princess Margaret Hospital, University Health Network, Toronto, ON.
Bezjak
A
A
Xu
W
W
Kane
G
G